Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LifeTech ScientificFRA:81X -2.16%95 Cash Ratio is 1.47 as of Jun. 2026, which is 5% below its 10-year median of 1.54. GuruFocus rates FRA:81X with a GF Score™ of 95/100 and a GF Value™ of €0.19. The stock has 5 warning signs investors should review. Among 834 Medical Devices & Instruments companies, LifeTech Scientific ranks better than 60.91% on this metric.
LifeTech Scientific has a Cash Ratio of 1.47. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for LifeTech Scientific's Cash Ratio or its related term are showing as below:
FRA:81X'
s Cash Ratio Range Over the Past 10 Years
Min: 0.78 Med: 1.54 Max: 3.36
Current: 1.46
During the past 13 years, LifeTech Scientific's highest Cash Ratio was 3.36. The lowest was 0.78. And the median was 1.54.
FRA:81X's Cash Ratio is ranked better than 60.91% of 834
companies
in the Medical Devices & Instruments industry
Industry Median: 0.945
vs FRA:81X: 1.46
LifeTech Scientific (FRA:81X) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
LifeTech Scientific Cash Ratio Related Terms
LifeTech Scientific Cash Ratio Historical Data
* Premium members only.
The historical data trend for LifeTech Scientific's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, LifeTech Scientific's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeTech Scientific Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's Cash Ratio distribution charts can be found below:
* The bar in red indicates where LifeTech Scientific's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LifeTech Scientific (FRA:81X) has a Cash Ratio of 1.47 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on LifeTech Scientific and its competitors. This is near median its historical median of 1.54. Over the past decade, LifeTech Scientific's Cash Ratio has ranged from 0.78 to 3.36. According to the industry distribution chart, LifeTech Scientific ranks #326 out of 834 companies in the Medical Devices & Instruments industry, placing it in the top 39.1%.
Is LifeTech Scientific's Cash Ratio too high?
LifeTech Scientific's current Cash Ratio of 1.47 is near median its 10-year median of 1.54. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 3.36. The Medical Devices & Instruments industry median Cash Ratio is 0.95. LifeTech Scientific's value of 1.47 is 55.6% above this industry median. Based on the distribution chart, LifeTech Scientific ranks #326 out of 834 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, LifeTech Scientific has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, LifeTech Scientific ranks #326 out of 834 companies for Cash Ratio. This puts LifeTech Scientific in the upper half of its industry. The industry median Cash Ratio is 0.95. LifeTech Scientific's value of 1.47 is 55.6% above this benchmark. Historically, LifeTech Scientific's own Cash Ratio has ranged from 0.78 to 3.36 over the past decade. While the company's 10-year median is 1.54 vs. the industry median of 0.95, LifeTech Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.95, based on 834 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeTech Scientific's current Cash Ratio of 1.47 is 55.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on LifeTech Scientific and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeTech Scientific's current Cash Ratio is 1.47, which is near median its own 10-year median of 1.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
LifeTech Scientific (FRA:81X) has a current Cash Ratio of 1.47. The stock's GF Value™ is €0.19, compared to a current price of €0.14 — trading 28.4% below its estimated fair value. The current Cash Ratio is 1.47, which is near median its 10-year median of 1.54 and 55.6% above the Medical Devices & Instruments industry median of 0.95. LifeTech Scientific's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For LifeTech Scientific (FRA:81X), the current Cash Ratio is 1.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeTech Scientific (FRA:81X) Overvalued in 2026?
Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued.
The current stock price of €0.14 is trading 28.4% below its estimated GF Value™ of €0.19.
Key valuation signals for FRA:81X:
Cash Ratio: 1.47 (near median its 10-year median of 1.54)
GF Value™: €0.19 vs. price of €0.14 (28.4% below fair value)
Industry Position: 55.6% above the Medical Devices & Instruments median (#326 of 834)
No single metric tells the full story. See the FRA:81X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
95GF Score
Get the complete analysis for FRA:81X
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:81X has been successfully added to your 
